Background: UGT1A1*28 polymorphism is associated with neutropenia and diarrhea in previous reports, while this study tried to investigate correlation with other toxicities like vomiting. Patients and Methods: This is a prospective case control study including all eligible cases of advanced colorectal cancer. The genotypes of UGT1A1*28 was assessed in the peripheral blood and/or in tissues by PCR. Patients were divided into two groups, Group 1: patients with no mutation, Group 2: patients with homo or hetero mutation. All patients received standard IFL regimen. Primary objectives were: 1) comparison between the 2 groups as regard vomiting, 2) assessment of the incidence of UGT1A1*28 polymorphism. Secondary objectives were: comparison between the 2 groups as regard: neutropenia, diarrhea, treatment delay, progressive diseases (PD), progression free survival (PFS) and overall survival (OS). Results: 46 cases of advanced colorectal cancer present to National Cancer Institute, Cairo University, aged between 19 and 71 years with a median age of 45 years were included and followed up during the period from September 2010 to January 2013 with a median follow-up of 9 months. UGT1A1*28 polymorphism was present in 20 patients (43%), of whom 15% are homozygous. Grade (II-IV) vomiting was found in 8.3% of Group 1 versus 52.5% of Group 2 (P = 0.01). Grade (II-IV) neutropenia was found in 20.8% of Group 1 versus 64.7% of Group 2 (P = 0.03). Grade (II-IV) diarrhea was found in 37.5% of patients of Group 1 and 27.5% of patients with Group 2. (P = 0.75). Treatment delay occurred in 29.16% of Group 1 versus 72.4% of Group 2 (P = 0.02). 25% of Group 1 showed PD versus 25% of Group 2 (P = 0.8). 1-year PFS was 19% in Group 1 versus 23% in Group 2 (P = 0.8) while there was a trend towards better OS in Group 1 (47% versus 35%) (P = 0.07). Conclusions: UGT1A1*28 polymorphism is present frequently (43%) in a Caucasian population and is associated with more vomiting, neutropenia and treatment delay.
Introduction
Colorectal cancer is the fourth most frequently diagnosed cancer and the second leading cause of cancer-related death in the United States [1] .
Because Irinotecan-based chemotherapy is a standard treatment in the management of metastatic CRC, interpatient variation of the enzymes involving its metabolism has been investigated extensively. Irinotecan (CPT-11) is a water-soluble analogue of 20(S)-camptothecin (CPT) and is an inactive prodrug. Its major metabolite, SN-38, is a potent active topoisomerase I-inhibitor and is known to be toxic [2] . One limitation of CPT-11 is the unpredictable and occasionally fatal gastrointestinal and hematologic toxicity, which varies greatly among individuals [3] . Predictive markers of CPT-11 toxicity, may thus be deduced from the CPT-11 metabolic pathway.
SN-38 undergoes glucuronide conjugation to the pharmacologically inactive SN-38 glucuronide by the hepatic uridine diphosphate glucuronosyltransferase 1A1 (UGT 1A1) enzyme. The glucuronidation of SN-38 may be protective against irinotecan-induced gastrointestinal toxicity [4] . This protection may be genetically determined, as UGT1A1 enzyme is known to exist in polymorphic states.
The specific polymorphism (UGT1A1*28) is the presence of a (TA)7TAA sequence in the promoter region, instead of (TA)6TAA. Studies with human liver microsomes, have demonstrated an association between this polymorphism and SN-38 glucuronidation, with significantly lower SN-38 glucuronidation rates in liver samples heterozygous or homozygous for the (TA)7TAA polymorphism [5] . Thus, knowledge of the UGT1A1 polymorphism status could help guide the selection of appropriate starting dosages, reducing the risk of severe toxicity and improving the chances that therapy could be maintained.
Roughly 10% of the US population is homozygous for UGT1A1*28. The frequency of the UGT1A1*28 allele varies among ethnicities, being highest in those of African (43%) or European (39%) descent and lowest in those of Asian (16%) descent [6] .
Among diplotypes of UGT1A genes, patients with the haplotypes harboring UGT1A1*6 or *28 had significantly reduced area under concentration curve ratios, with the effects of UGT1A1*6 or *28 being of a similar scale. In multivariate analysis, the homozygotes and double heterozygotes of *6 and *28 (*6/*6, *28/*28 and *6/ *28) were significantly associated with severe neutropenia in patients who received irinotecan monotherapy [7] .
Aim of Work
Primary objectives were: 1) Comparison between patients with wild and mutant UGT1A1*28 as regard vomiting.
2) Assessment of the incidence of UGT1A1*28 polymorphism.
Secondary objectives were:
Comparison between the 2 groups as regard: neutropenia, diarrhea, treatment delay, progressive diseases (PD), progression free survival (PFS) and overall survival (OS).
Patients and Methods
This is a prospective case control study including all eligible cases of advanced colorectal cancer. The genotypes of UGT1A1*28 was assessed in the peripheral blood and/or in tissues by PCR. Patients were divided into two groups, Group 1: patients with no mutation, Group 2: patients with homo or hetero mutation.
The study was conducted according to the Declaration of Helsinki and the guidelines for Good Clinical Practice. The local ethics committees approved the protocol, and informed consent was obtained from all patients before study entry.
Inclusion Criteria
Patient must have a histologically confirmed diagnosis of colon cancer. Stage III & Stage IV colon cancer. Patient is at least 18 years of age. Patient has a performance status of (ECOG Scale) ≤ 2. Patient has adequate bone marrow function, (WBC count ≥ 3.0 × 10 9 /L, ANC ≥ 1.5 × 10 9 /L platelet count ≥ 100 × 10 9 /L, hemoglobin level ≥ 9 g/L). Patient has adequate liver function; serum bilirubin < 1.5 × ULN, ALT and AST levels < three times normal values; ALT and AST levels < five times normal limits allowed in patients with known liver metastases. Patient has adequate Kidney function; plasma creatinine level < 1.5 times normal value. Patients should have compliance, mental state and geographic proximity that allow adequate follow up and they have to provide written informed consent before any study-specific procedure.
Exclusion Criteria
Patient is pregnant or breastfeeding. Patients with a "currently active" second malignancy. Patient who is currently involved in another clinical trial.
Treatment Plan
All patients received standard IFL (Irinotecan, 5FU, Leucovorin) regimen: Irinotecan 125 mg/m 2 weekly, Leucovorin 20 mg/m 2 weekly and 5FU 425 mg/m 2 weekly 4 weeks on 2 weeks off up to 6 months in responding patients.
Study Assessment
Pretreatment assessment included complete medical history and physical examination.
Further assessment conducted within 7 days before treatment included vital signs, performance status (EC-OG), complete blood count with differential and full biochemical panel, including liver and renal function tests were performed and repeated before each treatment course. CEA and CA19.9 were done at base line and then every 6 weeks. Radiological evaluation including computerized tomography (CT) scan of the chest, Abdomen & pelvis. Additional radiological imaging such as bone scan… were done if indicated. Imaging was repeated every 6 weeks.
Evaluation was done according to RECIST [8] .
Post treatment evaluation included:
Medical history and physical examination every 3 weeks. CBC and chemistry every 3 weeks. CT chest, abdomen and pelvis every 6 weeks. CEA and CA19.9 every 6 weeks. Other investigations were done if indicated. 
Toxicity
Toxicity evaluation was done according to the NCI Common Terminology Criteria for Adverse Events v4.0 (CT-CAE) [9] .
Statistical Methods
SPSS package (version 17.0) was used for data analysis. Mean and standard deviation were reported to describe quantitative data. The Chi-square and Fischer exact tests were used to evaluate the differences in the distribution of the variables. The Kaplan-Meier method was used to estimate the overall and progression free survival and the Log rank test to evaluate differences in survival among groups. P value of ≤0.05 was considered statistically si gnificant.
UGT1A1 Assessment
UGT1A1*28 polymorphism is characterized by the presence of an additional TA repeat in the TATA sequence of the UGT1A1 promoter ((TA)7TAA, instead of (TA)6TAA). In the current study, UGT1A1*28 polymorphism was assessed in the blood and/or tissues by PCR as previously described by Iyer et al., 2002 [10] and Akiyama et al., 2008 [11] .
1) Extraction of DNA from blood Mononuclear cells (MNCs)
Blood samples (7 ml) were collected from each patient on day 1 of the cycle (before starting chemotherapy). Density gradient separation of the MNCs from the collected blood was done using FicollHypaque Solution. DNA was extracted from the MNCs by phenol: chloroform: isoamyl alcohol after proteinase K digestion according to standard protocols. The extracted DNA was used to detect UGT1A1*28 polymorphism by PCR.
2) DNA Extraction from formalin fixed paraffin embedded tissues (FFPET)
For each tumor sample included in the study, five micron thick sections (5 sections) were obtained in a sterile, eppindorff, plastic tube. DNA was extracted from the homogenized FFPET sections by phenol: chloroform: isoamyl alcohol after proteinase K digestion according to standard protocols. Assessment of the concentration and purity of the extracted DNA was done using the spectrophotometer followed by visualization of an ethidium bromide-stained gel.
3) PCR amplification and genotyping of UGT1-A1*28
The isolated DNA was amplified by polymerase chain reaction (PCR) using the primer sequences and conditions of Iyer et al., 1999 [5] .
Primers: 5'-GTC ACG TGA CAC AGT CAA AC-3' 5'-TTT GCT CCT GCC AGA GGT T-3' PCR conditions
Initial denaturation step at 95˚C for 5 minutes, 30 cycles of: 95˚C for 30 seconds, 58˚C for 40 seconds, 72˚C for 40 seconds and final extension at 72˚C for 5 minutes.
Genotypes were assigned as follows: 6/6: homozygous for (TA)6TAA. 6/7: heterozygous for each (TA)6TAA/(TA)7TAA. 7/7: homozygous for (TA)7TAA. 5/8: heterozygous for each (TA)5TAA/(TA)8TAA.
Results
46 of advanced colorectal cancer cases presenting to National Cancer Institute, Cairo University, aged between 19 and 71 years with a median age of 45 years were included and followed up during the period from September 2010 to January 2013 with a median follow up of 9 months. 
Patients' Characteristics

Incidence of UGT1A1 Polymorphism
UGT1A1*28 polymorphism were present in 20 patients (43%), homozygous in 7 patients (15%) and heterozygous in 13 patients (28%) (Figure 1 ). Genotypes were: 6/6 in 26 patients (57%). 6/7 in 9 patients (20%). 7/7 in 7 patients (15%). 
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Toxicity
Vomiting: There was a statistically significant lower incidence of vomiting in patients with wild type UGT-1A1*28 compared to patients with mutant type: Grade (II-IV) vomiting was found in 8.3% of Group 1 versus 52.5% of Group 2 (P = 0.01) ( Table 2) . Neutropenia: There was a statistically significant lower incidence of neutropenia in patients with wild type UGT1A1*28 compared to patients with mutant type:
Grade (II-IV) neutropenia were found in 20.8% of Group 1 versus 64.7% of Group 2 (P = 0.03) ( Table 2) .
Diarrhea: Grade (II-IV) diarrhea was found in 37.5% of patients of Group 1 and 27.5% of patients with Group 2 (P = 0.75) ( Table 2 ).
Treatment Delay
There was a statistically significant lower incidence of treatment delay in patients with wild type UGT1A1*28 compared to patients with mutant type:
Treatment delay occurred in 29.16% of Group 1 versus 72.4% of Group 2 (P = 0.02) ( Table 2) .
Other toxicities included 1 case of thrombocytopenia grade III (in Group 1), 1 case of oral mucositis grade II 
Clinical Response
There was no significant difference between the 2 groups as regard clinical response. 25% of Group 1 showed PD versus 25% of Group 2 (P = 0.8) ( Table 3 ).
Survival Progression free survival (PFS):
There was no significant difference between the two groups as regard PFS. 1 year PFS was 19% in Group 1 versus 23% in Group 2 (P = 0.8) (Figure 2 ).
Overall survival (OS):
There was a trend towards better OS in patients with wild type UGT1A1*28 compared to patients with mutant type: One year OS in Group 1 was 47% versus 35% in Group 2 (P = 0.07) (Figure 3 ).
Discussion
The main problem with Irinotecan, which is an important drug in the treatment of colon cancer, is its toxicity. Patients receiving Irinotecan may experience some kind of severe toxicity, mainly diarrhea and neutropenia, resulting either in dose reduction, treatment withdrawal or dy- ing. UGT1A1*28 polymorphism is associated with neutropenia and diarrhea in previous reports, our study tried to investigate correlation with other toxicities like vomiting. This is a prospective case control study including all eligible patients presenting to National Cancer Institute (NCI), Cairo University during the period from September 2010 to January 2013. Patients were divided into 2 groups according to the condition of UGT1A1*28 gene polymorphism to wild (6/6) and mutant genotype (6/7 and 7/7). UGT1A1*28 polymorphism were present in 43% of patients, 15% homozygous (7/7) and 28% heterozygous (6/7). In Christoph Schulz et al. (2009) study, 9.5% of patients were homozygous and 49.5% were heterozygous for UGT1A1*28 [19] . In other studies, UGT1A1*28 polymorphism was present in a lower percentage such as Y. [11] [12] [13] [14] [15] [16] [17] [18] [19] . It is noteworthy that ethnic differences do exist in the UGT1A1*28 polymorphism, that's why there is differences between different studies of different ethnicities.
To no surprise, the current study showed that, UGT-1A1*28 polymorphism plays a significant role in the occurrence of hematological toxicity in patients treated with Irinotecan, especially neutropenia (20.8% vs. 64.7%, P = 0.03), this finding is in concordance with previous studies which showed similar results such as Chun-Yu et al. [10, [19] [20] [21] [22] [23] .
The current study showed no significant difference between the 2 study groups regarding risk of diarrhea (incidence 37.5% vs. 27.5%, P = 0.75) which may be attributed to small sample size of the present study. Some previous studies shows no difference like Christoph ) stated that patients with the (TA) 7TAA repeat in the promoter region of UGT1A1 may be expected to exhibit a higher incidence of diarrhea and neutropenia than those without the polymorphism [10, 20, 21] .
The interesting finding in this study is that, although all patients received premedication antiemetic, patients with UGT1A1*28 polymorphism had significantly more risk for vomiting than patients with wild type (52.5% in mutant type group versus 8.3% in the wild type group with P value of 0.01.). To our knowledge this is the first study to primarily address correlation between UGT-1A1*28 polymorphism and vomiting.
The current study showed no significant difference between the two groups regarding toxicity related dose adjustments (12.5% versus 32%, P = 0.25) whereas there was a statistically significant more dose delay in the mutant group (29% versus 72%, P = 0.02). These results are to a large extent similar to those of previous studies: In Christoph Schulz et al. (2009) [19, 20, 26] . Although the treatment delay was significantly greater in patients with the TA6/TA7 or TA7/TA7 genotypes when compared with wild type (72.4% versus 29.16% respectively), (P = 0.02) there was no significant difference between the two groups as regard clinical response, P value = 0.89. This goes with most of previous published studies like Christoph Schulz et al. (2009) study, which stated that the overall response rate (OR) was similar between patients carrying the (6/7, 7/7) or the wild genotype (6/6) (44.3% vs 43.2%, P = 0.75) and Chun-Yu et al. (2007) study which showed that the response rate to irinotecan-based chemotherapy were not affected with dose reduction that was required for the UGT1A1*28 polymorphism group (42.3% vs 45.1%; P = 0.80). (9, 10) But some studies such as Glenn et al. (2009) reported that, the *28 heterozygotes had a nonsignificantly higher response rate (RR, 1.09; 95% CI 0.83 -1.43), and *28 homozygotes had a significantly higher response rate (RR, 1.70; 95% CI 1.24 -2.33; P = < 0.001), and Toffoli et al. (2006) stated that, the UGT1A1 TA7/TA7 genotype seemed to be associated with increased clinical benefit and tumor response, as homozygous TA7/TA7 patients had a significantly reduced risk of PD or SD compared with the wild-type genotype (OR, 0.32; 95% CI, 0.12 to 0.86) and considering clinical benefit, the homozygous TA7/TA7 patients had a significantly lower risk of experiencing progression (OR, 0.19; 95% CI, 0.04 to 0.89) [24] .
In our study, we did not find a statistically significant difference between the two groups as regard PFS and OS, (PFS: 19% in wild group vs. 23% in mutant group, P = 0.8), although there was a trend toward a statistical significant difference for OS at one year (wild: 47% vs. 
Conclusion
The current study showed that UGT1A1*28 polymorphism is present frequently (43%) in a Caucasian population and is a key determinant for predicting irinotecaninduced toxicities as vomiting, neutropenia and treatment delay for patients with advanced colorectal cancer with a trend toward improvement of survival. Further prospective studies including larger sample size are warranted for using this polymorphism to optimize irinotecan-based chemotherapy with special emphasis on other toxicities which may be related to this polymorphism.
